Two different protein expression profiles of oral squamous cell carcinoma analyzed by immunoprecipitation high-performance liquid chromatography by Kim, Soung Min et al.
Kim et al. World Journal of Surgical Oncology  (2017) 15:151 
DOI 10.1186/s12957-017-1213-5RESEARCH Open AccessTwo different protein expression profiles of
oral squamous cell carcinoma analyzed by
immunoprecipitation high-performance
liquid chromatography
Soung Min Kim1, Dasul Jeong2, Min Keun Kim3, Sang Shin Lee2 and Suk Keun Lee2*Abstract
Background: Oral squamous cell carcinoma (OSCC) is one of the most dangerous cancers in the body, producing
serious complications with individual behaviors. Many different pathogenetic factors are involved in the carcinogenesis
of OSCC. Cancer cells derived from oral keratinocytes can produce different carcinogenic signaling pathways through
differences in protein expression, but their protein expression profiles cannot be easily explored with ordinary
detection methods.
Methods: The present study compared the protein expression profiles between two different types of OSCCs, which
were analyzed through immunoprecipitation high-performance liquid chromatography (IP-HPLC).
Results: Two types of squamous cell carcinoma (SCC) occurred in a mandibular (SCC-1) and maxillary gingiva (SCC-2),
but their clinical features and progression were quite different from each other. SCC-1 showed a large gingival
ulceration with severe halitosis and extensive bony destruction, while SCC-2 showed a relatively small papillary
gingival swelling but rapidly grew to form a large submucosal mass, followed by early cervical lymph node
metastasis. In the histological observation, SCC-1 was relatively well differentiated with a severe inflammatory
reaction, while SCC-2 showed severely infiltrative growth of each cancer islets accompanied with a mild inflammatory
reaction. IP-HPLC analysis revealed contrary protein expression profiles analyzed by 72 different oncogenic proteins.
SCC-1 showed more cellular apoptosis and invasive growth than SCC-2 through increased expression of caspases,
MMPs, p53 signaling, FAS signaling, TGF-β1 signaling, and angiogenesis factors, while SCC-2 showed more cellular
growth and survival than SCC-1 through the increased expression of proliferating factors, RAS signaling, eIF5A
signaling, WNT signaling, and survivin.
Conclusions: The increased trends of cellular apoptosis and invasiveness in the protein expression profiles of SCC-1
were implicative of its extensive gingival ulceration and bony destruction, while the increased trends of cellular
proliferation and survival in the protein profile of SCC-2 were implicative of its rapid growing tumor mass and
early lymph node metastasis. These analyses of the essential oncogenic protein expression profiles in OSCC provide
important information for genetic counseling or customized gene therapy in cancer treatment. Therefore, protein
expression profile analysis through IP-HPLC is helpful not only for the molecular genetic diagnosis of cancer but also
in identifying target molecules for customized gene therapy in near future.
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Squamous cell carcinoma (SCC) is the most frequent
and serious malignant tumor in the oral cavity. Although
it can be easily recognized by patients themselves or
detectable through simple clinical observation, the surgi-
cal removal of a SCC lesion is still difficult due to compli-
cated anatomical structures in the oral and maxillofacial
region composed of neuromuscular and dento-skeletal
tissues [1, 2]. Therefore, the combination treatment of
surgery, radiation, and chemotherapy is frequently recom-
mended following a pathological diagnosis. Surgical ther-
apy is the immediate and primary treatment to eradicate
the cancer tissue, and radiation therapy and chemotherapy
have been developed to induce cellular apoptosis and
arrest the growth of cancer cells [3–5].
Many cases of oral squamous cell carcinoma (OSCC)
recur even after radical excision of the tumor lesion, lead-
ing to a poor prognosis. Radiation therapy and chemo-
therapy are also sometimes ineffective on target cancer
cells depending on their oncogenic status in terms of
cellular differentiation, proliferation, apoptosis, survival,
migration, and other factors. In order to properly treat
OSCCs, pathological examination should be carefully per-
formed along with a molecular biological investigation to
determine the final diagnosis. Therefore, it is critical to de-
termine the cellular biological status of cancer cells, which
could be identified by their protein expression profiles for
different oncogenic signaling pathways [6, 7]. The present
study was performed to explore the molecular biological
dynamics in two different types of OSCCs through ana-
lysis with immunoprecipitation high-performance liquid
chromatography (IP-HPLC).
The two OSCCs showed different histological features
in cancer growth and propagation and had contrary
protein expression profiles implicative of their differ-
ences in carcinogenesis progression. Fortunately, a
sufficient amount of protein extract was obtained from
both cases of OSCCs during surgical excision of the tumor
mass followed by selective neck dissection. Each protein
extract was analyzed through IP-HPLC methods, which
have been much improved in data accuracy and statistical
analysis. These results are discussed along with a review of
the literature.
Methods
Two representative OSCCs were selected from the files of
the Department of Oral Pathology, Gangneung-Wonju
National University Dental Hospital (GWNUDH) under
the approval of institutional review board (IRB2016–11).
Both cases occurred in a mandibular molar (SCC-1) and
posterior maxillary area (SCC-2) in male patients who
were 65 and 69 years old. However, their clinical/radio-
logical features and pathological diagnosis were somewhat
different, as was their subsequent prognosis.Patients data
SSC-1 case showed more extensive bony destruction
around the mandibular molar area involving the upper
half of the mandibular body. The patient is a 65-year-old
man with large gingival ulceration with severe halitosis
on the lower left gingiva, 4 × 6 cm sized with extensive
buccal cortex bony invasion. It was diagnosed as a squa-
mous cell carcinoma with stage IV, thus partial mandi-
bulectomy with functional neck dissection with level I to
III, reconstruction with an R-plate and radial forearm
free flap. Post-operative radiotherapy with 7200 Gray,
and no recurrence or metastasis during 3 years and
6 months’ follow-up period (Fig. 1, Table 1).
SCC-2 case showed localized bony destruction around
the left maxillary posterior gingiva and early tumor
metastasis to the cervical lymph nodes. The patient was
a 69-year-old man with a relatively small papillary gin-
gival swelling mass on the left upper posterior gingiva.
This lesion grew rapidly to form a 4 × 6 cm sized sub-
mucosal mass and was diagnosed as a squamous cell
carcinoma with stage III. Extended maxillectomy with
functional neck dissection of level I to III combined with
buccal fat graft were operated. Although post-operative
radiotherapy with 6500 Gray was executed, there was
cervical node metastases during 4 years’ follow-up
period (Fig. 1, Table 1). Unfortunately, the patient is not
followed-up anymore.
Histological and immunohistochemical staining
The surgically removed specimens were fixed in 10%
neutral buffered formalin, processed routinely, and em-
bedded in paraffin. Histologic sections with a thickness
of 4 μm were mounted on glass slides and stained with
hematoxylin and eosin. Serial micro-sections were also
prepared for immunohistochemical staining using the
different antisera listed in Table 2. The immunohisto-
chemical reaction protocols used for this study differed
according to the target antigen and manufacturers’
protocols. Briefly, after deparaffinization and rehydration
of the tissue sections in xylene followed by ethanol,
sections were incubated with 0.5% hydrogen peroxide in
phosphate-buffered saline for 30 min. Primary anti-
human (rabbit/mouse/goat) polyclonal antibodies were
applied to each micro-section using the triple sandwich
indirect immunohistochemical method [8]. Microscopic
images were captured by a digital camera (DP-70®,
Olympus Co., Japan), followed by statistical analysis
using the image analysis program (IMT i-Solution®, ver
21.1, Vancouver, Canada).
IP-HPLC analysis for the protein extract obtained from
RAW 264.7 cell culture
One hundred microgram of each protein extract was
applied to the immunoprecipitation procedure using a
Fig. 1 Clinical and panoramic views of SCC-1 (a, b) and SCC-2 (c, d). A large gingival ulceration (a) with extensive bony destruction (b) in the left
posterior mandible of SCC-1, and a relatively small papillary gingival swelling (c) with bony destruction (d) in the left posterior maxilla of SCC-2
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The protein A/G agarose columns were separately pre-
incubated with 1 μg of each of the 25 different antisera,
including β-actin, Ki-67, PCNA, MAX, cMyc, E2F-1,
Rb-1, and MAD (Santa Cruz Biotech, USA). Briefly, the
protein samples were mixed with 5 mL of binding buffer
(150 mM NaCl, 10 mM Tris pH 7.4, 1 mM EDTA,
1 mM EGTA, 0.2 mM sodium vanadate, 0.2 mM PMSF,
and 0.5% NP-40) and incubated in the protein A/G agarose
columns at 10 °C for 1 h. The columns were placed on a
rotating stirrer during the incubation. After washing each
column with a sufficient amount of PBS solution (pH 7.3,
137 mM NaCl, 2.7 mM KCl, 43 mM Na2HPO4-7H2O, and
1.4 mM KH2PO4), the target protein was eluted with
150 μL of IgG elution buffer (Pierce Co., USA). The immu-
noprecipitated proteins were analyzed by HPLC (1100
series®, Agilent, USA) using a reverse phase column and
micro-analytical detector system (SG Hightech Co., Korea),
operated with a 0.15 M NaCl, 20% acetonitrile solution at
0.4 mL/min for 30 min, and analyzed by UV spectroscopy
at 280 nm. IP-HPLC analysis was performed simultan-
eously for both the control and experimental groups.
In the IP-HPLC results, the sample protein peak areas
(mAU*s) obtained from HPLC analysis in the negative
control were used to eliminate the antibody peak area
(mAU*s) [9, 10]. To compare the two different types of
SCCs, the protein peak area values of SSC-1 and SSC-2
were proportionally normalized by the α-tubulin value
and plotted as a bar and radial line graph.
Results
Histological and immunohistochemical findings
Histologically, SSC-1 was diagnosed as a well differenti-
ated SCC forming many cancer pearls (Fig. 2 A1-A2),
and SCC-2 was diagnosed as a poorly differentiatedTable 1 Clinical courses of SCC-1 and SCC-2
Patient Age Sex Size (cm) Location Stage Adjuvant therapy O
SCC-1 65 M 4 × 6 Lt Mn pT4N0M0 PORT P
R
SCC-2 69 M 2 × 3 Lt Mx pT3aN0M0 PORT Ex
lo
SCC squamous cell carcinoma, Lt left, Mx maxilla, Mn mandible, PORT post-operative
free flapOSCC exhibiting numerous infiltrating tumor islets into
the underlying connective tissue (Fig. 2 B1-B2).
In the immunohistochemical staining, the SSC-1
tumor cells were strongly positive for p53 (Fig. 2 A3),
TGF-β1, c-erbB2, caspase-9, PARP, FAS, FASL, MMP-2,
and MMP-9, while the SSC-2 tumor cells were strongly
positive for KRAS (Fig. 2 B3), STAT3, MPM2, eIF5A,
DHS, DOHH, snail, and survivin (data not shown).
IP-HPLC analysis from SCC-1 and SCC-2
The IP-HPLC analysis revealed that SCC-1 showed more
cellular transformation and apoptosis than SCC-2, while
SSC-2 showed more invasive growth and cellular
survival than SCC-1 (Figs. 3 and 4). In the protein
expression profile of SSC-1, the neoplastic proliferation
of tumor cells was supported by the overexpression of
E2F-1 and c-erbB2, and the cellular transformation and
differentiation of tumor cells were related to the over-
expression of TGF-β1, TGase-1, HO-1, hTERT, and p38
compared to SSC-2. Particularly, SSC-1 showed overex-
pression of apoptosis-related proteins, e.g., p53, BAD,
BAK, BID, BCL2, FAS, FASL, FLIP, caspase-3, caspase-
8, caspase-9, and PARP compared to SSC-2, indicating
that the oncogenic progression in SSC-1 was related to
the activation of p53 and FAS signaling compared to
SSC-2 (Fig. 3).
On the other hand, in the protein expression profile of
SSC-2, the neoplastic proliferation of the tumor cells
was related to the overexpression of PCNA, MPM2,
KRAS, STAT3, EGFR, and bFGF and supported by the
overexpression of protein translation factors, e.g., eIF5A,
DHS, and DOHH, compared to SSC-1. The p53 expres-
sion was partly suppressed by the overexpression of
MDM2, followed by the compensatory overexpression of
p16 and p21. The oncogenic progression was relevant toperation Follow-up Recurrence
artial mandibulectomy, SOHND,
-plate with RFFF reconstruction
3 years and 6 months None
tended maxillectomy, SOHND,
cal flap with buccal fat graft
4 years Neck metastasis
radiation therapy, SOHND supraomohyoid neck dissection, RFFF radial forearm
Table 2 Antibodies used in this study






5 EGFRb, c-erbB2b, TGF-β1d, bFGFa, HGFb
Proliferation-
related proteins
9 eIF5Ac, DHSc, DOHHc, PCNAc, MPM-2b,
CDK4a, cMyca, MAXa, hTERTa
Transcription
signaling proteins
3 NFkBb, p38a, E2F-1a
Apoptosis-related
proteins
14 FASa, FASLa, PARPa, BAXa, NOXAa, PUMAa,
BADa, BAKa, BIDa, caspase 3a, caspase 8a,
caspase 9a, FADDa, FLIPa,
Cell survival-related
proteins
3 pAKTc, MDM2a, BCL2a
Tumor suppressor
proteins
8 p16a, p21a, p53a, p63a, RB1a, PTENa,
PTCHa, NF-1b
Oncoproteins 9 14-3-3a, CEAc, STAT3a, survivind,
DMBT1a, maspina, snaila, KRASc, PIM1a






4 SHHa, β-cateninb, WNT1a, APCa
Matrix proteolysis
proteins
4 MMP-1c, MMP-2c, MMP-9a, elaffina
Angiogenesis-
related proteins
5 HIFd, VEGFd, vWFc, angiogenina, CMG2b
Total 72
Abbreviation: pAKT v-akt murine thymoma viral oncogene homolog
(phosphorylated at Thr 308), APC adenomatous polyposis coli, BAD BCL2
associated death promoter, BAK BCL2 antagonist/killer, BAX BCL2 associated X,
BCL-2 B-cell leukemia/lymphoma-2, BID BH3 interacting-domain death agonist,
CDK4 cyclin dependent kinase 4, CEA carcinoembryonic antigen, CMG2 capillary
morphogenesis protein 2, DHS deoxyhypusine synthase, DOHH deoxyhypusine
hydroxylase, DMBT1 deleted in malignant brain tumors 1, E2F-1 transcription
factor, EGFR epithelial growth factor receptor, eIF5A eukaryotic translation
initiation factor 5A, FADD FAS associated via death domain, FAK focal adhesion
kinase, FAS CD95/Apo1, FASL FAS ligand, bFGF basic fibroblast growth factor, FLIP
FLICE-like inhibitory protein, HGF hepatocyte growth factor, HIF hypoxia inducible
factor, HO-1 hemoxygenase 1, HSP-70 heat shock protein-70, KRAS V-Ki-ras2
Kirsten rat sarcoma viral oncogene homolog, MAX myc-associated factor X,
MDM2mouse double minute 2 homolog, MMP-1 matrix metalloprotease-1,
MPM-2 mitotic protein monoclonal 2, cMyc V-myc myelocytomatosis viral
oncogene homolog (avian), NF-1 neurofibromin-1, NFkB nuclear factor kappa-
light-chain-enhancer of activated B cells; NOXA phorbol-12-myristate-13-acetate-
induced protein 1; PARP poly-ADP ribose polymerase, PCNA proliferating cell
nuclear antigen, PIM1 pivotal integration site 1, PTCH patched homolog, PTEN
phosphatase and tensin homolog, PUMA p53 up-regulated modulator of
apoptosis, RB1 retinoblastoma 1, SHH sonic hedgehog, SHP-1 short helical
protein-1, SOS-1 Son of sevenless-1, STAT3 signal transducer and activator of
transcription-3, hTERT human telomerase reverse transcriptase, TGase-1
transglutaminase-1, TGF-β1 transforming growth factor-β1, TNFα tumor necrosis
factor-α, VEGF vascular endothelial growth factor, vWF von Willebrand factor
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KRAS, STAT3, WNT1, β-catenin, snail, and PTCH,
compared to SSC-1. The tumor cells also showed
increased cellular survival by the overexpression ofsurvivin, HSP-70, 14–3-3, and angiogenesis-related
proteins, e.g., HIF, vWF, CMG2, and bFGF, compared to
SSC-1 (Fig. 3).
The radial line graph shown in Fig. 4 clearly demon-
strates the differences in essential protein expression
profiles between SSC-1 and SSC-2. The protein expres-
sion of SSC-1 was shifted into the abortive cycles of
cellular differentiation, transformation, and apoptosis,
while the protein expression of SSC-2 was shifted into
the abortive cycles of oncogenic cellular growth and
survival (Fig. 4). These findings indicate that the carcino-
genesis progression processes of the two SCCs are differ-
ent even though they are both derived from keratinocytes
of the oral mucosa.
Discussion
The present study investigated the protein expression
profiles of two representative types of OSCCs. Although
these data were obtained from preliminary analysis in a
series of OSCC research, the recent strategy of molecu-
lar biological gene therapy urgently recommends the
collection of oncogenic signaling data from cancer cells
in each individual patient. Therefore, our study utilized
IP-HPLC analysis, which has been designed to perform
quantitative protein analysis using different but compar-
able protein samples.
During the past several years, liquid chromatography
tandem mass spectrometry (LC-MS/MS) has emerged as
an innovative analytical technology applicable to wide
ranges of sample’s molecules. Mass spectrometry (MS) is
an analytical technique that ionizes chemical species and
sorts the ions based on their mass-to-charge ratio, and
the mass spectrum is a plot of the ion signal as a func-
tion of the mass-to-charge ratio. These spectra are used
to determine the elemental or isotopic signature of a
sample, the masses of particles and of molecules, and to
elucidate the chemical structures of molecules, such as
peptides and other chemical compounds [11]. MS has
increased in speed, accuracy and use, and with the ability
of the mass spectrometers to identify increasing
numbers of proteins, the identification of undesirable
peptides has also increased [12]. Because the IP-HPLC
analysis is based on the antibody interaction with target
protein which may be specific and sensitive depending
on the epitope binding activity of antibody, it has to
utilize mathematical calculation for the relative protein
quantitation compared to the control. Therefore, it is
thought that the data obtained from IP-HPLC analysis
may be quite different from those from mass spectrom-
etry (MS-MS) which is able to provide the absolute
quantitation of proteins.
The histological differences between SSC-1 and SSC-2
were characterized by the dominant carcinogenic features
of cellular proliferation, apoptosis, invasion, and survival,
Fig. 2 Photomicrographs of two different types of OSCCs. A1-A3: SSC-1, well differentiated with many cancer pearls. B1-B3: SSC-2, poorly differentiated
with numerous infiltrating tumor islets. A1, A2, B1, B2: hematoxylin and eosin staining. A3 and B3: Immunostaining without background stain. A3: p53
staining is strongly positive in the tumor cells (arrows). B3: KRAS staining is strongly positive in the tumor cells (arrows)
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in cancer cells. In the immunohistochemical staining, the
tumor cells of SSC-1 were strongly positive for p53, TGF-
β1, c-erbB2, caspase-9, PARP, FAS, FASL, MMP-2, and
MMP-9, while the tumor cells of SSC-2 were strongly
positive for KRAS, STAT3, MPM2, eIF5A, DHS, DOHH,
snail, and survivin. These findings were similar to many
previous reports [13–18] illustrating how oncogenic signal-
ing functions in cancer cells, although their expression
levels were not quantitative but derived from the intensity
of peroxidase reaction with the chromogens 3,3′-diamino-
benzidine (DAB) or 3-amino-9-ethylcarbzole (AEC). There-
fore, a more precise detection system should be applied in
the investigation of protein expression for molecular
signaling as in this study.
The present IP-HPLC analysis disclosed that the
neoplastic proliferation of SCC-1 was related to theoverexpression of E2F-1 and c-erbB2, and the cellular
transformation and differentiation of SCC-1 was related to
the overexpression of TGF-β1, TGase-1, HO-1, hTERT,
and p38 compared to SSC-2. Particularly, SSC-1 showed
the overexpression of apoptosis-related proteins, e.g., p53,
BAD, BAK, BID, BCL2, FAS, FASL, FLIP, caspase-3,
caspase-8, caspase-9, and PARP, compared to SCC-2, indi-
cating that oncogenic progression in SSC-1 is related to
the activation of p53 and FAS signaling or cellular apop-
tosis compared to SSC-2. Thus, oncogenic signaling could
progress from multiple pathways involved in cellular pro-
liferation, differentiation, apoptosis, and survival in cancer
cells, and these results were similar to those of previous
reports [19–21].
On the other hand, in the protein expression profile of
SSC-2, the neoplastic proliferation of tumor cells was
related to the overexpression of PCNA, MPM2, KRAS,
Fig. 3 A bar graph comparing the essential oncogenic protein expression profiles between the two different types of oral squamous cell carcinomas.
SCC-1 (blue) showed more cellular transformation and apoptosis than SCC-2 (red) by the overexpression of caspases, MMPs, p53 signaling, FAS signaling,
TGF-β1 signaling, and angiogenesis factors, while SCC-2 showed more invasive growth and cellular survival than SCC-1 by the overexpression of
proliferating factors, RAS signaling, eIF5A signaling, Wnt signaling, and survivin
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overexpression of the protein translation factors eIF5A,
DHS, and DOHH compared to SSC-1. Therefore, it was
presumed that the major oncogenic signaling of SSC-2
was derived from RAS signaling supported by different
growth factors and active protein translation [22–24].
The p53 expression in SSC-2 was partly suppressed
by the overexpression of MDM2, followed by the com-
pensatory overexpression of p16 and p21; thereby, the
major tumor suppressor protein p53 might be down-
regulated and compensated by other cell cycle inhibi-
tors in SCC-2. Through comparison of the protein
expression profiles of SCC-1 and SCC-2, the oncogenic
progression of SSC-2 was assumed to be related to acti-
vation of the RAS and WNT signaling proteins, e.g.,
KRAS, STAT3, WNT1, β-catenin, snail, and PTCH,
compared to SSC-1 [25]. Therefore, the propagation of
SSC-2 was more aggressive with early cervical lymph
node metastasis and rapid recurrence compared to
SSC-1 even after radical surgery.
The tumor cells of SSC-2 also showed increased cellu-
lar survival by the overexpression of survivin [26], HSP-
70, 14-3-3, and the angiogenesis-related proteins HIF,vWF, CMG2, and bFGF compared to SSC-1 [27]. It
was presumed that cellular protection, survival, and
angiogenesis are closely associated with each other
and support or compensate their molecular signaling,
resulting in propagation of cancer cells. Therefore,
these signaling pathways could be oncogenic for SCC
as well as potentially important proteins for targeting
by anti-cancer drugs.
The radial line graph (Fig. 4) clearly demonstrates the
differences in essential protein expression profiles
between SSC-1 and SSC-2. The protein expression of
SSC-1 was shifted into the abortive cycles of cellular
differentiation, transformation, and apoptosis, while the
protein expression of SSC-2 was shifted into the abortive
cycles of oncogenic cellular growth and survival. These
findings indicate that the carcinogenesis progression of
these two SCCs are contrary even though they are both
derived from keratinocytes of the oral mucosa.
As cellular apoptosis was dominant in the oncogenic
signaling of SCC-1 with the overexpression of p53, it is
suggested that SCC-1 could be effectively treated by
radiation therapy, which can induce severe DNA damage
followed by cellular apoptosis. For SCC-2, which showed
Fig. 4 A radial line graph demonstrating the differential expression of essential oncogenic protein groups between SCC-1 (blue) and SCC-2 (red)
using the same data as in Fig. 3
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suggested to treat with multiple drugs targeting the
RAS and WNT pathways and related proteins. For
the “apoptosis-related proteins” in Table 2, the regula-
tion of apoptosis and cell proliferation by oncogenes,
tumor-suppressor genes and growth factors in OSCC
was already well known in many previous published
articles [28–30]. About the p53, TNF, and Fas signaling in
apoptosis, two theories of the direct initiation of apoptotic
mechanisms in mammals have been suggested (https://en.
wikipedia.org/wiki/Fas_ligand and https://en.wikipedia.
org/wiki/Apoptosis). The TNF-induced model and theFas-Fas ligand-mediated model, both involving recep-
tors of the TNF receptor (TNFR) family coupled to
extrinsic signals. Fas ligand (FasL or CD95L) is a type
II transmembrane protein that belongs to the TNF
family. Its binding with its receptor induces apoptosis.
Fas ligand/receptor interactions play an important
role in the regulation of the immune system and the
progression of cancer, including OSCC.
The present study is a simple demonstration of the
comparison of oncogenic protein expression profiles be-
tween different types of OSCCs, indicating that further
investigation should be performed by examining more
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methods. However, it is highly recommended that vari-
ous anti-cancer drugs be developed in order to target
specific oncogenic proteins in contrast to conventional
chemotherapy using aggressive alkylating agents such as
cisplatin, 5-fluorouracil, and methotrexate.
Conclusions
The increased trends of cellular apoptosis and inva-
siveness in the protein expression profile of SCC-1
implicated its extensive oral ulceration and bony de-
struction, while the increased trends of cellular prolif-
eration and survival in the protein profile of SCC-2
supported its rapid growing tumor mass and early
lymph node metastasis. These analyses of essential
oncogenic protein expression profiles in OSCCs pro-
vide important information for genetic counseling or
customized gene therapy in cancer treatment.
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